Live webcast fireside chat on Wednesday, June 21st at 12:00 PM ET
OCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K Equels, M.S., J.D., Executive Vice Chairman, Chief Executive Officer & President of AIM ImmunoTech, will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest on Wednesday, June 21, 2023 at 12:00 PM ET.
The exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space. These include multiple therapeutic categories and emerging technologies, which presenting companies at this year’s Maxim Healthcare Conference are focused on, and for many, that includes key data-driven events in 2023. Maxim Senior Analysts will host a wide range of biotechnology and medical device companies in a series of presentations and interactive discussions with CEOs and key management. Maxim will also be hosting several topical industry panels that promise to be timely and engaging.
This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member.
Click Here to Reserve Your Seat.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on Twitter, LinkedIn, and Facebook.
CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
Vancouver, British Columbia--(Newsfile Corp. - May 22, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF)…
Los Angeles, California--(Newsfile Corp. - May 22, 2025) - The St. Baldrick's Foundation, the largest…
BURLINGTON, Mass., May 22, 2025 /PRNewswire/ -- Clymb Clinical is proud to announce the launch…
A people-first culture continues to earn national and regional recognition BOCA RATON, Fla., May 22,…
BANGALORE, India, May 22, 2025 /PRNewswire/ -- Neurostimulation Devices Market is Segmented by Type (Spinal…
New purpose-driven brand campaign highlights the science behind R+F's skincare and the visible results it…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
